Determining the Complete Protection Time of an Insect Repellent With 30% Citriodiol® Against Three Species of Ticks.
NCT ID: NCT03708120
Last Updated: 2019-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
70 participants
INTERVENTIONAL
2018-11-15
2019-10-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
NCT05387083
Understanding Typhoid Disease After Vaccination
NCT01405521
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
NCT00489970
Control of Head Lice Infestations in Children and Adults
NCT00731718
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
NCT00109330
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To determine the typical consumer dose, twenty-five volunteers will be required to apply the repellent product from final consumer ready pump spray bottle to their forearm. Each volunteer will be asked to read the label and apply the repellent according to the instructions to their forearm. They will repeat the application three times. The amount applied by each subject across the three applications will be averaged, and then the average amount applied by each subject will be averaged to arrive at a "typical consumer dose". This typical consumer dose will be used as the application rate for the tick repellent efficacy trial. Three species are required by the EPA to demonstrate the effectiveness of a repellent. The following tick species have been chosen from the list of five species recommended by the EPA.
Ixodes scapularis - Also known as blacklegged ticks or deer ticks, this species is one of the principal vectors of Lyme disease. They are found in eastern and northern Midwest of the United States. The lifecycle takes approximately two years during which the tick develops from egg to larva, to nymph and finally adult. Larvae, nymphs and adults will all blood feed. Larvae usually feed from smaller mammals and birds, whilst nymphs and adults feed on larger mammals such as deer and humans.
Amblyomma americanum - The Lone Star Tick is found in the eastern United States and in Mexico. This species of hard tick can be a vector of human ehrlichiosis, tularaemia, and may trigger an allergy to the carbohydrate alpha gal found in mammalian meat.
Dermacentor variabilis - The American dog tick is usually found in central and eastern areas of the United States. Adults preferentially feed on large mammals such as dogs and humans, however immature stages will also feed on humans if the opportunity arises. They are the most common vector of Rocky Mountain spotted fever, and can also transmit tularaemia.
Rhipicephalus sanguineus - The brown dog tick is distributed worldwide, including across the United States. It is the vector of many pathogens, including Rickettsia rickettsia, the causative agent of Rocky Mountain spotted fever, Coxiella burnetii, causative agent of Q fever, Ehrlichia canis, and Rickettsia conorii. Dogs are the primary host for the brown dog tick in each of its life stages, but the tick may also bite humans or other mammals.
Ticks will be sourced from disease-free colonies at Oklahoma State University and housed at the London School of Hygiene \& Tropical Medicine, United Kingdom, under optimal environmental conditions of 25 ± 3 °C and greater than or equal to 80% Relative Humidity with a 16:8 hour photoperiod.
Single ticks will be exposed to participants' forearms following standardised treatment of one of the participant's forearms with repellent, in a laboratory setting. The treatment will be based on the dose derived from the dosimetry phase of the study, which will be submitted to EPA for review before proceeding to the repellency phase of testing. The treatment will be randomised to either the left or right arm of each participant for each test. There is no blinding employed since the outcome measures are based on tick behaviour. Twenty-five participants will be required for the consumer dose evaluation and to test the repellent against each of the tick species (preferably with a 50:50 ratio of males to females). Participants will test the product at a single dose against at least one of the three species.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Consumer Dose and Tick Repellency
Consumer dose: Dosimetry test of insect repellent application to forearms. Tick repellency: Treatment of forearm with insect repellent and exposure to ticks every 15 minutes for 10 hours.
Citrepel (Insect Repellent) EPA Reg. No. 84878-2
Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Citrepel (Insect Repellent) EPA Reg. No. 84878-2
Citrepel (Insect Repellent) EPA Reg. No. 84878-2 is a pump spray formulation containing the active ingredient Citriodiol®, a tradename for Oil of Lemon Eucalyptus (OLE, Chemical Abstracts Service (CAS) No.: 1245629-80-4). Citriodiol® is derived from Eucalyptus citriodora leaves and contains a minimum of 65% p-Menthane-3,8-diol (PMD, CAS: 42822-86-6) and other constituents occurring naturally in the essential oil source material. The repellent is manufactured by Citrefine International Ltd and will be supplied by them in the pump spray bottle the manufacturer intends to use when the product is marketed with instructions for use on the product label.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able and willing to give fully informed consent
* Male or female
* Aged 18 to 65 years
* Non-smoker or willing to refrain from smoking for 24 hours prior to and during each test
* Able to stand unsupported for periods of at least 5 minutes
* Willing to have hair clipped from the wrist area (3cm upwards from wrist line)
Exclusion Criteria
* Not in good general health, including:
* serious cardiac disorder (whether active or inactive)
* serious respiratory disorder
* compromised immune system
* history of anaphylaxis
* Localised skin disorders affecting the forearms where the product will be applied (including but not restricted to open wounds, eczema, psoriasis, dermatitis or open wounds)
* Participation in another clinical intervention study (excluding biting insect challenge studies\*) in the previous 3 months
* Participation in another biting insect challenge study\* in the previous 72 hours
* Known or suspected history of tick bite allergies
* Known allergy to Oil of Lemon Eucalyptus, or any ingredients of the test product
* Known phobia of ticks or tick bites
* Employees and spouses of employees of the Study Sponsor (Citrefine Inc.), arctec, and those directly line managed by Professor James Logan
* Students of the Professor James Logan, or any other faculty members involved in the study.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARCTEC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James G Logan
Role: STUDY_CHAIR
ARCTEC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ARCTEC
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
593
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.